The combination of the TLR9 agonist ODN1826 with either CTLA-4 or PD-1 blockade showed improved intertumoral CD8 + T-cell responses and suppressed tumor growth in a melanoma mouse model [130]. The gene discussed is CD8A; the disease is neoplasm.